Xbrane Biopharma AB (SE:XBRANE)
:XBRANE
Want to see SE:XBRANE full AI Analyst Report?
XBRANE Stock Chart & Stats
kr10.37
>-kr0.01(-2.10%)
At close: 4:00 PM EST
kr10.37
>-kr0.01(-2.10%)
Day’s Range― - ―
52-Week Rangekr5.42 - kr38.03
Previous CloseN/A
Volume1.93M
Average Volume (3M)117.17K
Market Cap
kr206.05M
Enterprise Valuekr93.47M
Total Cash (Recent Filing)kr86.59M
Total Debt (Recent Filing)kr58.31M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 05, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding20,605,349
10 Day Avg. Volume189,097
30 Day Avg. Volume117,165
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-61.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.14
Revenue Forecast (FY)kr186.50M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengtheningA materially stronger 2025 balance sheet meaningfully reduces leverage and refinancing risk, extending runway for R&D and partnering discussions. This durable capital base improves strategic optionality for clinical programs and deal-making over the next several quarters.
Diversified Monetization ModelA two-pronged model (partnering/licensing plus development/manufacturing services) reduces reliance on a single revenue stream. Licensing can deliver milestone and royalty durability while services provide recurring contract work, smoothing cash inflows and supporting long-term commercialization paths.
In-house Biologics Manufacturing CapabilityOwning process development and manufacturing for biologics is a durable competitive advantage: it accelerates clinical supply, lowers third-party dependency, supports margin capture on services, and makes the company a more attractive partner for out-licensing and contract manufacturing.
Bears Say
Persistent Cash BurnConsistent, deep negative operating and free cash flow forces ongoing external financing or dilutive capital raises. That structural cash burn constrains reinvestment, increases dilution risk, and limits the firm's ability to independently fund late-stage development or commercial scale-up.
Volatile And Declining RevenueRevenue volatility and multi-year declines weaken scale economics and make it harder to cover fixed manufacturing and development costs. This inconsistency impedes margin improvement, complicates partner negotiations, and raises execution risk for converting pipeline investments into stable cash flow.
Lack Of Operating ProfitabilityOperating losses across years indicate the core business hasn't reached sustainable profitability. Reliance on non-operating gains to report net income is not durable; absent structural margin improvement or recurring partner revenue, the company remains dependent on financing or one-time items.
Xbrane Biopharma AB News
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr5.42 and its highest was kr38.03 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is kr206.05M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is May 05, 2026 which is in 4 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Feb 20, 2026. The company reported -kr1.28 earnings per share for the quarter, beating the consensus estimate of -kr1.49 by kr0.21.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate is -0.52.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -kr1.28 in its last earnings report, beating expectations of -kr1.49. Following the earnings report the stock price went down -13.017%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
Technical Analysis
Ascelia Pharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Active Biotech AB
―
Immunicum AB
―
Options Prices
Currently, No data available
---